Behavioral neurologists specialize in diagnosing and treating cognitive and behavioral changes associated with neurological conditions. They are experts in the brain regions responsible for higher cognitive functions such as memory, executive function, and emotional regulation. These specialists assess patients with disorders such as Alzheimer’s disease, frontotemporal dementia, and traumatic brain injury, using both cognitive tests and brain imaging to evaluate neurological damage. Behavioral neurologists also study the neurological underpinnings of psychiatric disorders, including mood disorders, psychosis, and anxiety. They work closely with patients and their families to manage symptoms and improve quality of life through a combination of pharmacological treatment, cognitive rehabilitation, and behavioral therapies. These specialists also focus on understanding how brain injury and neurodegeneration lead to changes in behavior, cognition, and personality. Behavioral neurologists contribute to the development of personalized care plans, integrating findings from neuroimaging and neuropsychological testing to target specific brain regions affected by the disorder. As clinical researchers, they investigate new therapies for cognitive rehabilitation, aiming to improve cognitive function and emotional well-being. With advances in neuroplasticity, they strive to enhance recovery outcomes for patients with neurodegenerative diseases, offering hope for those affected by these often-debilitating conditions.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States